Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961933 | 1.00 | GDA (0.44) | GDAACHEGSK3AGSK3BCDK5 | |
| SCHEMBL30572345 | 1.00 | GDA (0.44) | GDAACHEGSK3AGSK3BCDK5 | |
| Hydrochloric Acid SCHEMBL3957661 | 0.97 | GDA (0.43) | GDAACHEGSK3AGSK3BCDK5 | |
| Trifluoroacetic Acid SCHEMBL3954861 | 0.80 | BRAF (0.33) | GDAACHEGSK3AGSK3BPDE3B | |
| SCHEMBL932546 | 0.80 | KDM4E (0.46) | GDAACHEGSK3AGSK3BCDK5 | |
| SCHEMBL29545868 | 0.80 | KDM4E (0.46) | GDAACHEGSK3AGSK3BCDK5 | |
| Hydrochloric Acid SCHEMBL28868510 | 0.78 | KDM4E (0.44) | GDAACHEGSK3AGSK3BCDK5 | |
| Water SCHEMBL6479622 | 0.78 | KDM4E (0.44) | GDAACHEGSK3AGSK3BCDK5 | |
| Hydrochloric Acid SCHEMBL30431695 | 0.78 | KDM4E (0.44) | GDAACHEGSK3AGSK3BCDK5 | |
| SCHEMBL5438576 | 0.77 | KDM4E (0.40) | GDAACHEGSK3AGSK3BCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | claimed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | claimed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | claimed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | claimed |
| CN-117447298-A | Synthetic method of halogenated methyl difluoromethyl benzene | 上海泰坦科技股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3845538-B1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2022-09-01 | — | — | US | disclosed |
| CN-110577543-B | Dihydroimidazopyrazinone compound, composition containing dihydroimidazopyrazinone compound and application of dihydroimidazopyrazinone compound | 深圳市塔吉瑞生物医药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110577543-B | Dihydroimidazopyrazinone compound, composition containing dihydroimidazopyrazinone compound and application of dihydroimidazopyrazinone compound | 深圳市塔吉瑞生物医药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110577543-B | Dihydroimidazopyrazinone compound, composition containing dihydroimidazopyrazinone compound and application of dihydroimidazopyrazinone compound | 深圳市塔吉瑞生物医药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080090806-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | GDA 888/4885ACHE 3752/4885GSK3A 3146/4885 |
| US-20220273650-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | GDA 3204/4885ACHE 4830/4885GSK3A 705/4885 |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | AURKA, AURKC, AURKB | GDA 4621/4885ACHE 3135/4885GSK3A 167/4885 |
| US-20080090806-A1 | Cgrp Receptor Antagonists | CCKBR, BDKRB1, BDKRB2 | GDA 2122/4885ACHE 793/4885GSK3A 2605/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | GDA 4394/4885ACHE 162/4885GSK3A 718/4885 |
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | GDA 3629/4885ACHE 3236/4885GSK3A 712/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | GDA 2272/4885ACHE 2815/4885GSK3A 327/4885 |
| US-20220024907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | GDA 2213/4885ACHE 4826/4885GSK3A 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.